JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 13, 2009; DOI: 10.1124/jpet.108.146225


0022-3565/09/3291-252-261$20.00
JPET 329:252-261, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Erratum
Right arrow All Versions of this Article:
jpet.108.146225v1
jpet.108.146225v2
329/1/252    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minuesa, G.
Right arrow Articles by Martinez-Picado, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minuesa, G.
Right arrow Articles by Martinez-Picado, J.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Transport of Lamivudine [(-)-β-L-2',3'-Dideoxy-3'-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3Formula

Gerard Minuesa, Christopher Volk, Míriam Molina-Arcas, Valentin Gorboulev, Itziar Erkizia, Petra Arndt, Bonaventura Clotet, Marçal Pastor-Anglada, Hermann Koepsell, and Javier Martinez-Picado

IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain (G.M., I.E., B.C., J.M.-P.); Institüt für Anatomie und Zellbiologie, Universität Würzburg, Würzburg, Germany (C.V., V.G., P.A., H.K.); Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Institut de Biomedicina, Universitat de Barcelona and Centro de Investigación Biomédica en Red-Enfermedades Hepáticas y Digestivas, Barcelona, Spain (M.M.-A., M.P.-A.); and Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain (J.M.-P.)

Nucleoside reverse transcriptase inhibitors (NRTIs) need to enter cells to act against the HIV-1. Human organic cation transporters (hOCT1–3) are expressed and active in CD4+ T cells, the main target of HIV-1, and have been associated with antiviral uptake in different tissues. In this study, we examined whether NRTIs interact and are substrates of hOCT in cells stably expressing these transporters. Using [3H]N-methyl-4-phenylpyridinium, we found a high-affinity interaction among abacavir [[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-cyclopent-2-enyl]methanol sulfate] (ABC); <0.08 nM], azidothymidine [3'-azido-3'-deoxythymidine (AZT); <0.4 nM], tenofovir disoproxil fumarate (<1.0 nM), and emtricitabine (<2.5 nM) and hOCTs. Using a wide range of concentrations of lamivudine [(-)-β-L-2',3'-dideoxy-3'-thiacyitidine (3TC)], we determined two different binding sites for hOCTs: a high-affinity site (Kd1 = 12.3–15.4 pM) and a low-affinity site (Kd2 = 1.9–3.4 mM). Measuring direct uptake of [3H]3TC and inhibition with hOCT substrates, we identified 3TC as a novel substrate for hOCT1, 2, and 3, with hOCT1 as the most efficient transporter (Km = 1.25 ± 0.1 mM; Vmax = 10.40 ± 0.32 nmol/mg protein/min; Vmax/Km = 8.32 ± 0.40 µl/mg protein/min). In drug-drug interaction experiments, we analyzed cis-inhibition of [3H]3TC uptake by ABC and AZT and found that 40 to 50% was inhibited at low concentrations of the drugs (Ki = 22–500 pM). These data reveal that NRTIs experience a high-affinity interaction with hOCTs, suggesting a putative role for these drugs as modulators of hOCT activity. Finally, 3TC is a novel substrate for hOCTs and the inhibition of its uptake at low concentrations of ABC and AZT could have implications for the pharmacokinetics of 3TC.


Received for publication September 16, 2008
Accepted January 12, 2009.

Address correspondence to: Javier Martinez-Picado, IrsiCaixa Foundation, Hospital Germans Trias i Pujol, E-08916, Badalona, Barcelona, Spain. E-mail: jmpicado{at}irsicaixa.es




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
C. Volk, V. Gorboulev, A. Kotzsch, T. D. Muller, and H. Koepsell
Five Amino Acids in the Innermost Cavity of the Substrate Binding Cleft of Organic Cation Transporter 1 Interact with Extracellular and Intracellular Corticosterone
Mol. Pharmacol., August 1, 2009; 76(2): 275 - 289.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
W.-K. Lee, M. Reichold, B. Edemir, G. Ciarimboli, R. Warth, H. Koepsell, and F. Thevenod
Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule
Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1504 - F1513.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.